Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Bordonaro says the only choice for patients who have RAS wild-type disease and fail on oxaliplatin- and irinotecan-based chemotherapy is panitumumab. However, this therapy cannot be used if the patient received panitumumab plus oxaliplatin-based chemotherapy in the first-line setting.

The only option for patients who have received prior panitumumab therapy is regorafenib, Bordonaro says. This recomendation is based on the recent data of the CORRECT trial, a phase III study that tested the efficacy of regorafenib in comparison to placebo in patients in the third-line.

Videos

Dr. Bordonaro on the Treatment of Advanced CRC

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).

Bordonaro says the first-line treatment options for patients with advanced CRC are influenced by 

 mutation status. Physicians have two options for treating patients in this space, Bordonoaro says.

 are treated with chemotherapy plus anti-EGFR agents, such as panitumumab or cetuximab.

Data from the PRIME trial, which compared FOLFOX plus panitumumab to panitumumab alone, showed that patients treated with panitumumab plus FOLFOX had an improvement in overall survival. The retrospective study of the CRYSTAL study and data from the FIRE study show that cetuximab prolongs overall survival longer than 30 months in patients who have 

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Roberto Bordonaro, MD

Articles

Dr. Bordonaro on the Treatment of Advanced CRC

Dr. Bordonaro on First-Line Treatment Options for mCRC